Product: Cirodap Tablet — Indapamide Tablets BP 2.5 mg
Composition: Each film-coated tablet contains Indapamide BP, equivalent to Indapamide hemihydrate 2.5 mg (label wording subject to verification).
Usage: Treatment of high blood pressure (hypertension).
Category: Anti Hypertensive / Cardiac Drugs
Therapeutic Category: Thiazide-like Diuretic / Antihypertensive
SKU: Indapamide Tablets
Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations
Indapamide Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.
For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.
Indapamide is a thiazide-like diuretic used to treat high blood pressure. Healthy Life Pharma Pvt. Ltd. lists Cirodap Tablet — Indapamide BP 2.5 mg as a film-coated tablet. The supplied product composition confirms only this 2.5 mg variant; a 1.5 mg sustained-release variant is mentioned in descriptive material but not confirmed as an available SKU.
Manufactured by: Healthy Life Pharma Pvt. Ltd. (WHO-GMP Certified)
Exported by: Healthy Inc (Star Export House)
| Parameter | Specification |
|---|---|
| Brand / Product | Cirodap Tablet / Indapamide Tablets BP |
| Composition per tablet | Indapamide BP, equivalent to Indapamide hemihydrate 2.5 mg (as described in supplied label text; verify exact salt/hydrate wording against approved artwork) |
| Strength | 2.5 mg |
| Dosage form | Film-coated tablet |
| Pharmacopoeial designation | BP (as supplied) |
| Therapeutic class | Thiazide-like diuretic / Antihypertensive |
| CAS number (indapamide) | 26807-65-8 |
| Other formulation | 1.5 mg sustained-release mentioned in background description; availability not verified |
| Packaging / shelf life | Confirm against approved product specification and pack artwork |
Consistent indapamide tablet quality depends on appropriate API characterization, validated blending and compression, film-coating controls, and suitable protection from moisture and light where indicated by stability studies. Specific HPMC sustained-release matrices or solid-dispersion processes should not be attributed to the confirmed Cirodap 2.5 mg product without product-specific documentation.
Product-specific quality control should address identity, assay, content uniformity, dissolution, related substances, microbial requirements where applicable, and stability, using the approved BP specification and validated analytical methods. Numeric dissolution limits and shelf-life claims must be supported by the actual batch and stability records.
Indapamide acts principally by inhibiting sodium and chloride reabsorption in the distal nephron and also has vascular effects that contribute to blood-pressure lowering. It is used in the treatment of hypertension; other uses depend on the approved local label. It may affect potassium, sodium, uric acid and glucose, so it should not be described as universally metabolically neutral.
For contract-manufacturing and export enquiries, request the applicable certificate of analysis, manufacturing licence, approved pack artwork, stability information and registration documents where available. CTD/ACTD dossiers, certificates and destination-market approvals require product-specific verification.
Q: Which formulation is confirmed?
A: Cirodap, film-coated Indapamide BP 2.5 mg tablets.
Q: Is 1.5 mg sustained-release included?
A: The description mentions it, but no corresponding composition was provided; confirm availability separately.
Q: Can indapamide lower potassium?
A: Yes. Low potassium and low sodium can occur; clinicians may request periodic blood tests.
Q: Is Cirodap identical to Natrilix SR?
A: No such equivalence is established here. The supplied Cirodap product is 2.5 mg, while sustained-release formulations have different release characteristics.
Use only as prescribed and according to the approved local label. Indapamide 2.5 mg immediate-release tablets are commonly prescribed once daily, often in the morning, but dose selection depends on blood pressure, kidney function, electrolytes and other medicines. Sustained-release tablets are not interchangeable on a milligram-for-milligram basis without clinical guidance.
Store in the original pack in a dry place, protected from excessive heat and moisture, according to the approved product label. Keep out of reach of children.